Applied Therapeutics, Inc. (APLT) Insider Trading Activity
NASDAQ$0.6029
Market Cap
$85.36M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
438 of 877
Rank in Industry
253 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
APLT Insider Trading Activity
APLT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $6,720,817 | 16 | 100 |
Related Transactions
| Chinoporos Constantine | See Remarks | 0 | $0 | 2 | $17,348 | $-17,348 |
| Funtleyder Leslie D. | Chief Financial Officer | 0 | $0 | 4 | $172,614 | $-172,614 |
| Perfetti Riccardo | Chief Medical Officer | 0 | $0 | 4 | $284,352 | $-284,352 |
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | 10 percent owner | 0 | $0 | 2 | $1.27M | $-1.27M |
| Shendelman Shoshana | President and CEO | 0 | $0 | 4 | $4.98M | $-4.98M |
About Applied Therapeutics, Inc.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Insider Activity of Applied Therapeutics, Inc.
Over the last 12 months, insiders at Applied Therapeutics, Inc. have bought $0 and sold $6.72M worth of Applied Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Applied Therapeutics, Inc. have bought $661,035 and sold $8.04M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $65,367 was made by Kanter Stacy J. (director) on 2023‑12‑01.
List of Insider Buy and Sell Transactions, Applied Therapeutics, Inc.
| 2025-03-04 | Sale | Perfetti Riccardo | Chief Medical Officer | 10,366 0.0081% | $0.44 | $4,561 | -9.14% | |
| 2025-03-04 | Sale | Funtleyder Leslie D. | See Remarks | 14,502 0.0114% | $0.44 | $6,381 | -9.14% | |
| 2025-03-04 | Sale | Chinoporos Constantine | See Remarks | 447 0.0004% | $0.44 | $197 | -9.14% | |
| 2025-02-06 | Sale | Perfetti Riccardo | Chief Medical Officer | 86,078 0.0743% | $0.61 | $52,508 | -19.27% | |
| 2025-02-06 | Sale | Funtleyder Leslie D. | See Remarks | 22,950 0.0198% | $0.61 | $14,000 | -19.27% | |
| 2025-02-06 | Sale | Chinoporos Constantine | See Remarks | 28,117 0.0243% | $0.61 | $17,151 | -19.27% | |
| 2024-08-22 | Sale | Perfetti Riccardo | Chief Medical Officer | 22,681 0.0206% | $5.83 | $132,230 | -84.79% | |
| 2024-08-22 | Sale | Funtleyder Leslie D. | Chief Financial Officer | 13,530 0.0123% | $5.83 | $78,880 | -84.79% | |
| 2024-08-14 | Sale | Shendelman Shoshana | President and CEO | 119,591 0.1056% | $5.93 | $709,175 | -85.36% | |
| 2024-08-13 | Sale | Shendelman Shoshana | President and CEO | 357,423 0.3288% | $6.18 | $2.21M | -85.85% | |
| 2024-08-12 | Sale | Shendelman Shoshana | President and CEO | 300,000 0.267% | $5.98 | $1.79M | -85.01% | |
| 2024-06-06 | Sale | Shendelman Shoshana | President and CEO | 61,795 0.0519% | $4.32 | $266,954 | -1.22% | |
| 2024-06-06 | Sale | Perfetti Riccardo | Chief Medical Officer | 22,003 0.0185% | $4.32 | $95,053 | -1.22% | |
| 2024-06-06 | Sale | Funtleyder Leslie D. | Chief Financial Officer | 16,980 0.0143% | $4.32 | $73,354 | -1.22% | |
| 2024-06-05 | Sale | ALEXANDRIA REAL ESTATE EQUITIES, INC. | 10 percent owner | 150,000 0.1261% | $4.24 | $636,000 | +0.68% | |
| 2024-06-04 | Sale | ALEXANDRIA REAL ESTATE EQUITIES, INC. | 10 percent owner | 150,000 0.131% | $4.21 | $631,500 | +5.33% | |
| 2024-03-14 | Sale | Shendelman Shoshana | President and CEO | 318,573 0.2652% | $5.39 | $1.72M | -16.07% | |
| 2024-03-14 | Sale | Perfetti Riccardo | Chief Medical Officer | 110,804 0.0922% | $5.39 | $597,234 | -16.07% | |
| 2024-03-14 | Sale | Hansard Adam | Chief Commercial Officer | 48,871 0.0407% | $5.39 | $263,415 | -16.07% | |
| 2024-03-14 | Sale | Funtleyder Leslie D. | Chief Financial Officer | 28,727 0.0239% | $5.39 | $154,839 | -16.07% |
Total: 130
*Gray background shows transactions not older than one year
Insider Historical Profitability
18.42%
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | 10 percent owner | 5855077 4.1356% | $3.53M | 2 | 6 | +18.45% |
| Shendelman Shoshana | President and CEO | 4690839 3.3133% | $2.83M | 6 | 15 | +32.95% |
| Perfetti Riccardo | Chief Medical Officer | 890409 0.6289% | $536,827.59 | 1 | 61 | <0.0001% |
| Funtleyder Leslie D. | See Remarks | 390459 0.2758% | $235,407.73 | 0 | 22 | |
| Chinoporos Constantine | See Remarks | 271436 0.1917% | $163,648.76 | 0 | 2 | |
| Hansard Adam | Chief Commercial Officer | 732919 0.5177% | $441,876.87 | 0 | 5 | |
| MARCUS JOEL S | director | 365360 0.2581% | $220,275.54 | 2 | 3 | +10.6% |
| Silberstein Charles | Chief Financial Officer | 87803 0.062% | $52,936.43 | 0 | 1 | |
| Kanter Stacy J. | director | 63000 0.0445% | $37,982.70 | 3 | 0 | +15.24% |
| Mahadevan Chids | See Remarks | 9800 0.0069% | $5,908.42 | 0 | 1 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$4,968,419 | 139 | 5.13% | $85.32M | |
$49,091,668 | 110 | 13.11% | $89.82M | |
$2,600,095 | 110 | 13.50% | $76.15M | |
$22,608,361 | 93 | 3.94% | $80.87M | |
$4,898,715 | 46 | 40.75% | $75.18M | |
$671,363 | 44 | -16.23% | $86.98M | |
$909,129 | 37 | 42.19% | $87.8M | |
$53,912,175 | 35 | -8.02% | $79.79M | |
$7,147,964 | 34 | 24.78% | $87.83M | |
$36,079,815 | 31 | 43.23% | $92.08M | |
$277,862 | 15 | 59.79% | $92.27M | |
Applied Therapeutics, Inc. (APLT) | $28,281,140 | 14 | 18.42% | $85.36M |
$14,562,799 | 14 | -4.77% | $75.9M | |
$17,567,343 | 12 | 34.87% | $74.96M | |
$135,589,307 | 10 | 32.46% | $90.66M | |
$15,724,108 | 9 | 124.63% | $74.06M | |
$299,343 | 6 | -44.75% | $87.28M | |
$20,729,984 | 5 | 51.71% | $77M | |
$16,003,671 | 3 | 55.38% | $88.23M |
APLT Institutional Investors: Active Positions
| Increased Positions | 67 | +40.61% | 38M | +32.73% |
| Decreased Positions | 76 | -46.06% | 39M | -33.46% |
| New Positions | 27 | New | 2M | New |
| Sold Out Positions | 45 | Sold Out | 8M | Sold Out |
| Total Postitions | 156 | -5.45% | 114M | -0.73% |
APLT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vestal Point Capital, Lp | $5,290.00 | 8.1% | 11.5M | +10M | +904.37% | 2024-12-31 |
| Vr Adviser, Llc | $4,596.00 | 7.04% | 9.99M | +165,591 | +1.69% | 2024-12-31 |
| Propel Bio Management, Llc | $4,423.00 | 6.77% | 9.62M | +3M | +46.4% | 2024-12-31 |
| Blackrock, Inc. | $4,394.00 | 6.73% | 9.55M | +255,227 | +2.75% | 2025-03-31 |
| Morgan Stanley | $4,055.00 | 6.21% | 8.82M | -1M | -10.99% | 2024-12-31 |
| Schonfeld Strategic Advisors Llc | $4,031.00 | 6.17% | 8.76M | +8M | +2,458.26% | 2024-12-31 |
| Knoll Capital Management, Llc | $2,668.00 | 4.08% | 5.8M | +225,000 | +4.04% | 2024-12-31 |
| Vanguard Group Inc | $2,552.00 | 3.91% | 5.55M | +305,282 | +5.82% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $2,494.00 | 3.82% | 5.42M | +5M | +2,511.86% | 2024-12-31 |
| Deutsche Bank Ag | $2,055.00 | 3.15% | 4.47M | +30,520 | +0.69% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.